Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 6
1997 1
1998 3
2001 3
2002 1
2003 1
2004 1
2005 1
2007 1
2008 4
2009 1
2011 6
2012 5
2013 4
2014 5
2015 8
2016 12
2017 6
2018 4
2019 10
2020 7
2021 3
2022 3
2023 2
2024 8
2025 8
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. Armstrong DK, et al. Among authors: behbakht k. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. J Natl Compr Canc Netw. 2022. PMID: 36075393
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK. Liu J, et al. Among authors: behbakht k. J Natl Compr Canc Netw. 2024 Oct;22(8):512-519. doi: 10.6004/jnccn.2024.0052. J Natl Compr Canc Netw. 2024. PMID: 39413835
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. Among authors: behbakht k. J Natl Compr Canc Netw. 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. J Natl Compr Canc Netw. 2021. PMID: 33545690
Decoding the dynamic tumor microenvironment.
Clauset A, Behbakht K, Bitler BG. Clauset A, et al. Among authors: behbakht k. Sci Adv. 2021 Jun 4;7(23):eabi5904. doi: 10.1126/sciadv.abi5904. Print 2021 Jun. Sci Adv. 2021. PMID: 34088677 Free PMC article. Review.
EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner.
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. Nguyen LL, et al. Among authors: behbakht k. Mol Cancer Res. 2024 Dec 3;22(12):1117-1127. doi: 10.1158/1541-7786.MCR-24-0067. Mol Cancer Res. 2024. PMID: 39136655 Free PMC article.
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. Among authors: behbakht k. J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039. J Natl Compr Canc Netw. 2019. PMID: 31390583
A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. Corr BR, et al. Among authors: behbakht k. Gynecol Oncol. 2025 Sep;200:58-67. doi: 10.1016/j.ygyno.2025.07.008. Epub 2025 Jul 22. Gynecol Oncol. 2025. PMID: 40700852 Free PMC article. Clinical Trial.
Cross-assay RNA modeling reveals cancer biomarkers.
Townsend HA, Jordan KR, Wolsky RJ, Van Kleunen LB, Davidson NR, Behbakht K, Sikora MJ, Dowell RD, Clauset A, Bitler BG. Townsend HA, et al. Among authors: behbakht k. bioRxiv [Preprint]. 2026 May 5:2026.04.30.722009. doi: 10.64898/2026.04.30.722009. bioRxiv. 2026. PMID: 42146664 Free PMC article. Preprint.
ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer.
McMellen A, Yamamoto TM, Qamar L, Sanders BE, Nguyen LL, Ortiz Chavez D, Bapat J, Berning A, Post MD, Johnson J, Behbakht K, Nurmemmedov E, Chuong EB, Bitler BG. McMellen A, et al. Among authors: behbakht k. Mol Cancer Res. 2023 Jan 3;21(1):3-13. doi: 10.1158/1541-7786.MCR-22-0102. Mol Cancer Res. 2023. PMID: 36149636 Free PMC article.
113 results